Skip to main content
Premium Trial:

Request an Annual Quote

Lynx Posts Sharp Drop in Revenues, Stable Losses for Q1

NEW YORK, May 14 (GenomeWeb News) - Lynx Therapeutics yesterday reported sharply declined revenues and stable losses for the first quarter of the year.

 

Revenues totaled $1.3 million, down from $3.3 million during the first quarter of last year.

 

Research and development costs declined to $2.5 million, from $3.6 million in the year-ago period.

 

The company posted a net loss of $4.2 million, or $.66 per share, up from $4 million, or $.85 per share, during the same period last year.

 

As of March 31, Lynx had   cash and cash equivalents of $5.6 million.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.